Related references
Note: Only part of the references are listed.Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants A Nationwide Propensity Score-Weighted Study
Arnar B. Ingason et al.
ANNALS OF INTERNAL MEDICINE (2021)
Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study
Alma R. Oskarsdottir et al.
BLOOD (2021)
Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study
Amitava Banerjee et al.
HEART (2020)
Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon
Petar Stankovic et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents
Eran Glikson et al.
LARYNGOSCOPE (2019)
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin
Thorsten Send et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2019)
A systematic review of propensity score methods in the acute care surgery literature: avoiding the pitfalls and proposing a set of reporting guidelines
T. L. Zakrison et al.
EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY (2018)
The role of oral anticoagulants in epistaxis
A. M. S. Buchberger et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2018)
Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
Alexandros Briasoulis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants
V L'Huillier et al.
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES (2018)
Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon
T. C. Sauter et al.
CLINICAL OTOLARYNGOLOGY (2018)
Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement
Andrew B. Goldstone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
George Ntaios et al.
STROKE (2017)
Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
Abdulaali R. Almutairi et al.
CLINICAL THERAPEUTICS (2017)
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial
Pall T. Onundarson et al.
LANCET HAEMATOLOGY (2015)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation
Lizheng Mao et al.
VASCULAR (2014)
Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant
Francisco Javier Garcia Callejo et al.
ACTA OTORRINOLARINGOLOGICA ESPANOLA (2014)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients
Sandra K. Thygesen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study
J. Smith et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Systematic overview of warfarin and its drug and food interactions
AM Holbrook et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Share Paper
